Protocol Ledger

NCT06949852 · Phase III · COMPLETED

Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia

Interventional Phase III clinical trial protocol NCT06949852 sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-07 Enrollment: 289 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06949852
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)289 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06949852
Protocol FieldVerified Registry Value
NCT IdentifierNCT06949852
Consolidated Lead SponsorYangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment289 participants (ACTUAL)
Registered Start Date2024-08-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06949852
Hospital Research SiteLocationSite Profile
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
Sichuan Provincial People's HospitalChengdu, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital Of Fujian Medical UniversityFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI